Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 1.00 |
| ▸ | KDM1A | O60341 | 9/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000407 | 1.00 | TRPV1 (1.00) | TRPV1KDM1AMAPTSMN1; SMN2TP53 | |
| SCHEMBL13675643 | 0.91 | TRPV1 (1.00) | TRPV1KDM1AMAPTSMN1; SMN2TP53 | |
| SCHEMBL4001584 | 0.90 | TRPV1 (1.00) | TRPV1MAPTSMN1; SMN2TP53MEN1 | |
| SCHEMBL4001591 | 0.90 | TRPV1 (1.00) | TRPV1MAPTSMN1; SMN2TP53MEN1 | |
| SCHEMBL13675665 | 0.87 | TRPV1 (0.80) | TRPV1MAPTSMN1; SMN2TP53MEN1 | |
| SCHEMBL13675645 | 0.85 | TRPV1 (0.78) | TRPV1MAPTSMN1; SMN2MEN1MAPK1 | |
| SCHEMBL30568744 | 0.84 | KDM1A (0.79) | TRPV1KDM1AMAPTSMN1; SMN2TP53 | |
| SCHEMBL13675757 | 0.82 | TRPV1 (0.78) | TRPV1MAPTSMN1; SMN2TP53MEN1 | |
| SCHEMBL9695844 | 0.81 | TRPV1 (1.00) | TRPV1MAPTSMN1; SMN2TP53MEN1 | |
| SCHEMBL13675629 | 0.81 | TRPV1 (1.00) | TRPV1MAPTSMN1; SMN2TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | claimed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | claimed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | claimed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | claimed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080095720-A1 | Vitamin A, Vitamin B3, humectant, aloe vera, pigmentary or sunscreen grade metal oxide, Vitamin C, resorcinol, an antisebum agent, or a hydroxy fatty acid and capsazepine; wrinkle resistance cosmetics | CONOPCO, INC., D/B/A UNILEVER (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008046788-A1 | SKIN BENEFIT COMPOSITIONS WITH A VANILLOID RECEPTOR ANTAGONIST | UNILEVER PLC (GB) | 2008-04-24 | — | — | WO | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885KDM1A 3440/4885MAPT 755/4885 |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885KDM1A 3440/4885MAPT 755/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885KDM1A 3014/4885MAPT 653/4885 |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885KDM1A 3440/4885MAPT 755/4885 |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885KDM1A 3440/4885MAPT 755/4885 |
| US-20080095720-A1 | Vitamin A, Vitamin B3, humectant, aloe vera, pigmentary or sunscreen grade metal oxide, Vitamin C, resorcinol, an antisebum agent, or a hydroxy fatty acid and capsazepine; wrinkle resistance cosmetics | RBP4, ALOX15, ALOX15B | TRPV1 15/4885KDM1A 2929/4885MAPT 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.